Enhertu granted Priority Review in the US for patients with HER2 …
WEB2 days ago · With Enhertu (trastuzumab deruxtecan), a HER2-directed antibody drug conjugate (ADC), AstraZeneca and Daiichi Sankyo are aiming to improve outcomes in previously treated HER2-positive and HER2-low metastatic breast cancer and are exploring its potential in earlier lines of treatment and in new breast cancer settings.
ENHERTU® Granted Priority Review in the U.S. for Patients
WEB2 days ago · ENHERTU (5.4 mg/kg) is approved in more than 65 countries worldwide for the treatment of adult patients with unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months of completing adjuvant ...
ENHERTU - Business Wire
WEB2 days ago · HER2-Low Metastatic Breast Cancer DESTINY-Breast04 The safety of ENHERTU was evaluated in 371 patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who...
ENHERTU® Granted Priority Review in the U.S. for Patients with …
WEB2 days ago · The safety of ENHERTU was evaluated in 257 patients with unresectable or metastatic HER2-positive breast cancer who received at least one dose of ENHERTU 5.4 mg/kg intravenously once every three weeks in DESTINY-Breast03.
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority …
WEB2 days ago · To bring much-needed treatment options to patients with triple-negative breast cancer, an aggressive form of breast cancer, AstraZeneca is evaluating the potential of datopotamab deruxtecan alone and in combination with immunotherapy durvalumab, capivasertib in combination with chemotherapy, and …
Enhertu demonstrated a median progression-free survival of 13.2 …
WEBJun 2, 2024 · Detailed positive results from the DESTINY-Breast06 Phase III trial showed that Enhertu (trastuzumab deruxtecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low …
Enhertu Effective in HER2-Positive Metastatic Breast Cancer
WEBOct 19, 2021 · In people with metastatic HER2-positive breast cancer, the targeted drug trastuzumab deruxtecan (Enhertu) markedly lengthened progression-free survival compared with trastuzumab emtansine (Kadcycla), new study results show.
Enhertu Approved for Any HER2-Positive Solid Cancer - NCI
WEBMay 3, 2024 · Targeted Therapy Improves Survival for Metastatic “HER2-Low” Breast Cancer. Enhertu expected to become new standard for treating metastatic breast cancer with low HER2 protein levels.
Enhertu Breast Cancer Drug Results in ‘Unheard-of’ Survival …
WEBJune 7, 2022. The patients had metastatic breast cancer that had been progressing despite rounds of harsh chemotherapy. But a treatment with a drug that targeted cancer cells with laserlike...
FDA grants accelerated approval to fam-trastuzumab deruxtecan …
WEBOn April 5, 2024, the Food and Drug Administration granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or...